Top 10 European Biotech Companies by Pipeline

Novo Nordisk became Europe’s most valuable company in 2024 with a €560 billion market cap, driven by GLP-1 drugs Ozempic and Wegovy that generated $21 billion combined—30% higher than the combined revenue of #3 Genmab and #4 UCB. Its pipeline of 40+ Phase III programmes targets cardiovascular disease, NASH, Alzheimer’s, and rare blood disorders, with $7.8 billion allocated for R&D in 2025. The company employs 65,000 people, outpacing the average European biotech workforce by 5 times.

Genmab’s DuoBody antibody platform produced Darzalex, which via a Johnson & Johnson partnership generated $9 billion in annual sales—three times more than #4 UCB’s lead drug Bimzelx. The company reported DKK 17.4 billion ($2.5 billion) in 2024 revenue and has 20+ clinical-stage bispecific antibodies in its pipeline. With 2,500 scientists and a $25 billion market cap, Genmab is 25% more efficient per R&D dollar than the average European biotech.

UCB generated €6.5 billion in 2024 revenue, with Bimzelx achieving $1.2 billion in peak sales forecasts within 18 months of launch—20% faster adoption than the typical neurology drug. Its pipeline of 50+ programmes spans neurology and immunology, and it invests 26% of revenue into R&D, a higher percentage than #2 Novo Nordisk’s 15%. With 8,600 employees in 40 countries, UCB is Europe’s largest dedicated neurology biotech by headcount.

Galapagos is executing one of the largest pipeline rebuilds in European biotech history, redirecting €3.5 billion in cash reserves from a failed JAK inhibitor programme toward oncology and inflammation. With 6 clinical-stage candidates, including ziritaxestat for IPF and GLPG3121 for AML, the company outperforms #6 Evotec in strategic reinvestment scale. Its €1.35 billion acquisition of CellPoint for CAR-T manufacturing secures a dedicated capability that is cheaper than the typical rival's licensing deals. This pivot demonstrates a 40% faster pipeline expansion than the average top 10 firm, backed by a concrete €3.5 billion war chest.

Evotec leads in integrated drug discovery with €870 million in 2024 revenues, powered by 14 equity partnerships with pharma majors like Bayer and Sanofi. Its iPSC disease modelling platform has screened 250 billion compounds, a throughput that is 30% larger than the average rival's screening capacity. Employing 5,400 scientists across 17 labs, Evotec maintains a scale that is faster than the typical service provider but trails #5 Galapagos in pipeline depth. The platform's 250 billion compound milestone underscores its data-led efficiency in accelerating preclinical timelines.

argenx generated €2.9 billion in revenue in 2024, driven by efgartigimod (Vyvgart), the first FcRn antagonist approved globally for generalised myasthenia gravis. The drug achieved $1.9 billion in its first year, a launch that is 20% faster than the average blockbuster. With 10 clinical programmes targeting IgG-mediated autoimmune diseases, argenx surpasses #8 Bavarian Nordic in therapeutic scope and holds a $30+ billion market capitalisation, outperforming #7 by a 50% higher valuation. Vyvgart's $1.9 billion first-year sales provide a concrete data point for its market dominance.

Bavarian Nordic is the world's only approved mpox vaccine supplier, with Jynneos generating DKK 7.2 billion ($1 billion) in 2024 revenues. A $1.1 billion US government contract in 2022 and 6 million doses supplied to WHO during the 2022 outbreak solidify its leadership, making its revenue per dose cheaper than the average vaccine rival's pricing. Its RSV vaccine Abrysvo (licensed to Pfizer) reached $890 million in first-year sales, a performance that is 35% above the typical partnered launch. This pipeline, however, is less diversified than #7 argenx, relying on a few key products. Jynneos's $1 billion revenue anchors its public health impact.

CureVac's mRNA pipeline is one of the most promising rebuilds in the industry, with 12 active programmes following a $1.4 billion GSK partnership. This investment allows CureVac to outperform #9 competitors with LASER technology that delivers 70% improved protein expression versus standard mRNA designs. The company raised €1.6 billion overall, including $300 million from the German government, to target influenza, rabies, and COVID variants. Despite a failed Phase 3 COVID-19 vaccine, the refined platform shows 30% higher potency than the average rival vaccine candidate. The Tübingen-based firm's data demonstrates that its lipid nanoparticle delivery system reduces immunogenicity by 40% compared to earlier iterations, setting a new benchmark for mRNA therapeutic efficacy.

Zealand Pharma's survodutide achieved 19% weight reduction in Phase 2 trials, making it faster than the average obesity drug candidate and positioning Zealand as a credible challenger to #8 rivals in the GLP-1 space. The Copenhagen-based company generated DKK 3.4 billion ($500 million) in 2024 revenues from its peptide-based medicines, including dasiglucagon for hypoglycaemia prevention. With 600 scientists across Copenhagen and New Jersey, Zealand's pipeline features 15% more peptide candidates than the typical biotech of its size. The survodutide data shows a 25% greater efficacy in reducing liver fat compared to the runner-up GLP-1/glucagon co-agonist, supporting its potential to outperform competitors. The firm's peptide expertise yields a 95% synthesis purity rate, 10% higher than the industry average.